The Australian Nuclear Science and Technology Organisation has agreed to provide U.S. firm Lantheus Medical Imaging with molybdenum-99 derived from low-enriched uranium for use in its TechneLite generator line being marketed in U.S. and Canada. Lantheus and ANSTO are working with U.S. and Canadian regulators to obtain the necessary approvals for the distribution of LEU-derived Mo-99 in U.S. and Canadian markets.

Related Summaries